GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bristol-Myers Squibb Co (NYSE:BMY) » Definitions » ROE %

Bristol-Myers Squibb Co (Bristol-Myers Squibb Co) ROE %

: 24.13% (As of Dec. 2023)
View and export this data going back to 1952. Start your Free Trial

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Bristol-Myers Squibb Co's annualized net income for the quarter that ended in Dec. 2023 was $7,048 Mil. Bristol-Myers Squibb Co's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $29,214 Mil. Therefore, Bristol-Myers Squibb Co's annualized ROE % for the quarter that ended in Dec. 2023 was 24.13%.

The historical rank and industry rank for Bristol-Myers Squibb Co's ROE % or its related term are showing as below:

BMY' s ROE % Range Over the Past 10 Years
Min: -20.16   Med: 16.12   Max: 38.18
Current: 26.18

During the past 13 years, Bristol-Myers Squibb Co's highest ROE % was 38.18%. The lowest was -20.16%. And the median was 16.12%.

BMY's ROE % is ranked better than
93.2% of 1000 companies
in the Drug Manufacturers industry
Industry Median: 4.435 vs BMY: 26.18

Bristol-Myers Squibb Co ROE % Historical Data

The historical data trend for Bristol-Myers Squibb Co's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bristol-Myers Squibb Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.48 -20.16 18.96 18.88 26.53

Bristol-Myers Squibb Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.38 28.78 25.99 25.30 24.13

Competitive Comparison

For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bristol-Myers Squibb Co ROE % Distribution

For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's ROE % distribution charts can be found below:

* The bar in red indicates where Bristol-Myers Squibb Co's ROE % falls into.



Bristol-Myers Squibb Co ROE % Calculation

Bristol-Myers Squibb Co's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=8025/( (31061+29430)/ 2 )
=8025/30245.5
=26.53 %

Bristol-Myers Squibb Co's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=7048/( (28998+29430)/ 2 )
=7048/29214
=24.13 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Bristol-Myers Squibb Co  (NYSE:BMY) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=7048/29214
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(7048 / 45908)*(45908 / 93211)*(93211 / 29214)
=Net Margin %*Asset Turnover*Equity Multiplier
=15.35 %*0.4925*3.1906
=ROA %*Equity Multiplier
=7.56 %*3.1906
=24.13 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=7048/29214
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (7048 / 6696) * (6696 / 7612) * (7612 / 45908) * (45908 / 93211) * (93211 / 29214)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.0526 * 0.8797 * 16.58 % * 0.4925 * 3.1906
=24.13 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Bristol-Myers Squibb Co ROE % Related Terms

Thank you for viewing the detailed overview of Bristol-Myers Squibb Co's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Bristol-Myers Squibb Co (Bristol-Myers Squibb Co) Business Description

Address
430 East 29th Street, 14th Floor, New York, NY, USA, 10016
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.
Executives
Christopher S. Boerner officer: EVP, Chief Commercial Officer 21823 30TH DRIVE S, BOTHELL WA 98021
Samuels Theodore R. Ii director 1990 E. GRAND AVE., EL SEGUNDO CA 90245
Cari Gallman officer: EVP, Corporate Affairs BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Ann Powell Judge officer: SVP, Human Resources BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543
Robert M Plenge officer: EVP, Chief Research Officer C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Rupert Vessey officer: Pres., Research & Early Dev. C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Adam Lenkowsky officer: EVP, Chief Commercial Officer BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Giovanni Caforio officer: EVP & Chief Commercial Officer BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543
David V Elkins officer: EVP, Chief Financial Officer C/O BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES NJ 07417
Deepak Bhatt director BRISTOL MYERS SQUIBB, 430 E. 29TH STREET, 14TH FLOOR, NEW YORK NY 10016
Sandra Leung officer: Vice President and Secretary C/O BRISTOL MYERS SQUIBB CO, 345 PARK AVE, NEW YORK NY 10164
Sharon Greenlees officer: SVP & Controller BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Karin Shanahan officer: EVP, Glob. Prod. Dev. & Supply BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Gregory Scott Meyers officer: EVP, Chief Digital & Tech Off. BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Autenried Paul Von officer: SVP, Enterp. Services & CIO BRISTOL-MYERS SQUIBB COMPANY, 100 NASSAU PARK BOULEVARD, PRINCETON NJ 08543